Mineralys Therapeutics Inc.
05/22/2026 | Press release | Distributed by Public on 05/22/2026 14:50
Proxy Results (Form 8-K)
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 21, 2026, Mineralys Therapeutics, Inc. (the Company) held its 2026 annual meeting of stockholders (the Annual Meeting). The following matters (the Proposals) were voted upon by the stockholders with the final voting results as shown:
Proposal 1 - To elect three directors to serve as Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders.
|
Name
|
For
|
Withhold
|
Broker Non-Votes
|
|||||||||||||||||
|
Srinivas Akkaraju, M.D., Ph.D.
|
40,667,555
|
26,447,538
|
5,569,960
|
|||||||||||||||||
|
Brian Taylor Slingsby, M.D., Ph.D., M.P.H.
|
42,487,140
|
24,627,953
|
5,569,960
|
|||||||||||||||||
|
Daphne Karydas
|
66,626,766
|
488,327
|
5,569,960
|
|||||||||||||||||
Proposal 2 - To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|||||||||||||||||
|
72,648,272
|
9,516
|
27,265
|
0
|
|||||||||||||||||
Both Proposals were approved, each receiving the affirmative requisite vote of the holders of shares of the Company's common stock.
Each Proposal is described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 8, 2026.
Mineralys Therapeutics Inc. published this content on May 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 22, 2026 at 20:50 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]